Table 3:
Follow-up imaging data
| Characteristics | US | % | MRI | % |
|---|---|---|---|---|
| No. of patients | 11 | 44% | 23 | 51% |
| Median delay between onset of symptoms and follow-up exam (days) (IQR) | 89 (71.5–171) | |||
| PVI | 11 | 100% | 15 | 65% |
| Complete PVI disappearance | 0 | 0% | 8 | 35% |
| PVI decrease | 11 | 100% | 15 | 65% |
| PVI stability | 0 | 0% | 0 | 0% |
| PVI increase | 0 | 0% | 0 | 0% |
| Lumen caliber narrowing | 2 | 18% | 1 | 4% |
| Median PVI largest diameter (mm) (IQR) | 1.5 (0.9–2.4) | 2.9 (2.0–3.5) | ||
| Median decrease of the PVI largest diameter | 61% | 55% | ||
| Median PVI span (mm) (IQR) | 9 (5–10) | 13 (9.5–16) | ||
| Median decrease of the PVI span | 62% | 50% | ||
| Persistence of a soft intimal plaque | 4 | 50% | 3 | 33% |
| Disappearance of a soft intimal plaque | 4 | 50% | 6 | 67% |
| PVI enhancement | NA | 12 | 52% | |